Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Multiple Sclerosis is often associated with severe functional deficits resulting in a range
of progressive impairments. Approximately 80% of patients have bladder symptoms at the time
of diagnosis and up to 97% will have bladder symptoms during the course of the disease. To
date, the vast majority of treatment has been centered on the use of medications to control
"bladder spasms" and the use of catheters to help patients empty the bladder. There have been
very few studies looking at medications like Alfuzosin that may help in controlling bladder
symptoms in Multiple Sclerosis. Alfuzosin has been shown to significantly improve voiding
symptoms and bladder emptying in patients with prostatic enlargement. There have been no
controlled studies yet to determine whether this treatment helps patients with Multiple
Sclerosis. The purpose of this study is to determine if Alfuzosin improves bladder symptoms
and quality of life in patients with Multiple Sclerosis.